Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Orthofix Medical (OFIX) EBITDA (2016 - 2026)

Orthofix Medical has reported EBITDA over the past 17 years, most recently at $17.7 million for Q1 2026.

  • For the quarter ending Q1 2026, EBITDA rose 134.53% year-over-year to $17.7 million, compared with a TTM value of $117.1 million through Mar 2026, up 146.03%, and an annual FY2025 reading of $118.9 million, up 192.13% over the prior year.
  • EBITDA came in at $17.7 million for Q1 2026, down from $37.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $85.8 million in Q4 2022 to a low of -$210.5 million in Q4 2023.
  • Median EBITDA over the past 5 years was $7.1 million (2022), compared with a mean of -$20.3 million.
  • The largest YoY upside for EBITDA was 2444.94% in 2023 against a maximum downside of 951.15% in 2023.
  • Over 5 years, EBITDA stood at $85.8 million in 2022, then plummeted by 345.35% to -$210.5 million in 2023, then increased by 2.47% to -$205.3 million in 2024, then surged by 118.46% to $37.9 million in 2025, then plummeted by 53.23% to $17.7 million in 2026.
  • Per Business Quant, the three most recent readings for OFIX's EBITDA are $17.7 million (Q1 2026), $37.9 million (Q4 2025), and $32.5 million (Q3 2025).